Why the study?
What are the mechanisms, risks, and management strategies for cardiovascular toxicities associated with tyrosine kinase inhibitors?
What are the mechanisms, risks, and management strategies for cardiovascular toxicities associated with tyrosine kinase inhibitors?
Routine cardiovascular monitoring, including ECG, biomarkers, and blood pressure, is recommended during TKI therapy due to varying risks of cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
May warrant edema monitoring with dasatinib; leaves open comparative TKI cardiotoxicity mechanisms.
Chaar et al. (2018) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: